256 related articles for article (PubMed ID: 19598262)
1. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
[TBL] [Abstract][Full Text] [Related]
2. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
Kim A; Serada S; Enomoto T; Naka T
Expert Opin Ther Targets; 2010 Sep; 14(9):963-71. PubMed ID: 20673185
[TBL] [Abstract][Full Text] [Related]
3. Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers.
Matsuzaki S; Serada S; Morimoto A; Ueda Y; Yoshino K; Kimura T; Naka T
Expert Opin Ther Targets; 2014 Apr; 18(4):403-14. PubMed ID: 24479491
[TBL] [Abstract][Full Text] [Related]
4. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
Matsuzaki S; Enomoto T; Serada S; Yoshino K; Nagamori S; Morimoto A; Yokoyama T; Kim A; Kimura T; Ueda Y; Fujita M; Fujimoto M; Kanai Y; Kimura T; Naka T
Int J Cancer; 2014 Apr; 134(8):1796-809. PubMed ID: 24150977
[TBL] [Abstract][Full Text] [Related]
5. Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
Takaya A; Peng WX; Ishino K; Kudo M; Yamamoto T; Wada R; Takeshita T; Naito Z
Int J Oncol; 2015 Apr; 46(4):1573-81. PubMed ID: 25633807
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.
Choi CH; Sung CO; Kim HJ; Lee YY; Song SY; Song T; Kim J; Kim TJ; Lee JW; Bae DS; Kim BG
Hum Pathol; 2013 Jun; 44(6):1017-23. PubMed ID: 23290009
[TBL] [Abstract][Full Text] [Related]
7. Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells.
Mogami T; Yokota N; Asai-Sato M; Yamada R; Koizume S; Sakuma Y; Yoshihara M; Nakamura Y; Takano Y; Hirahara F; Miyagi Y; Miyagi E
PLoS One; 2013; 8(11):e80359. PubMed ID: 24244679
[TBL] [Abstract][Full Text] [Related]
8. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
9. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
Li M; Yin J; Mao N; Pan L
Oncol Rep; 2013 Jan; 29(1):58-66. PubMed ID: 23064469
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
[TBL] [Abstract][Full Text] [Related]
14. Annexin IV is differentially expressed in clear cell carcinoma of the ovary.
Miao Y; Cai B; Liu L; Yang Y; Wan X
Int J Gynecol Cancer; 2009 Dec; 19(9):1545-9. PubMed ID: 19955935
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
Itamochi H; Kigawa J; Terakawa N
Cancer Sci; 2008 Apr; 99(4):653-8. PubMed ID: 18377417
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.
Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
J Gynecol Oncol; 2017 May; 28(3):e33. PubMed ID: 28382796
[TBL] [Abstract][Full Text] [Related]
18. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
19. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.
Ohishi Y; Oda Y; Uchiumi T; Kobayashi H; Hirakawa T; Miyamoto S; Kinukawa N; Nakano H; Kuwano M; Tsuneyoshi M
Clin Cancer Res; 2002 Dec; 8(12):3767-75. PubMed ID: 12473588
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]